← All trials
NCT04645550
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 22, 2020
- Primary completion
- Nov 22, 2022
- Completion date
- Nov 22, 2022
- First posted
- Nov 27, 2020
- Last posted
- Dec 29, 2020
- Enrollment
- 120
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Yangzhou UniversityLead sponsor
- Yangzhou UniversityOverall official - principal investigator
- Yangzhou UniversityStudy director
- Yangzhou UniversityStudy chair
- Yangzhou UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.